177lu-psma-617,225ac-psma-617
novartis
['psma-617 ', 'pcsm', 'prostate', '177lu,psma,617', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
overall survival and tolerability was deemed comparable when radionuclide 177lu-psma-617 was given within 6 months or more than 6 months after radium-223 for metastatic castration-resistant prostate cancer. #pcsm #gu23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.